prednisone and glp-1 Advances in receptor agonists delivery systems for obesity diabetes Central glucagon-like peptide 1 receptor

One of the central considerations in the translational trajectory of GLP-1RAs is their CNS pharmacokinetics

Each recipe includes nutrition facts and simple cooking instructions

The clinical trial results are unlike anything we have seen before in pharmaceutical weight loss research

Currently, the FDA has approved three GLP-1 RAs for obesity treatment: liraglutide, semaglutide and tirzepatide

Tirzepatide suppresses palatable food intake by selectively reducing preference for fat in rodents In collaboration with Eli Lilly, we showed that the dual GLP-1/GIP agonist Tirzepatide robustly decreases preference for palatable foods by selectively decreasing lipid consumption